Treatment and Survival in Acute Leukemia: A New South Wales Study Comparing Adolescents and Young Adults with Children and Adults

Table 3

Age disparity in treatment items (OR^a, 95% CI) among patients with ALL and AML in NSW, 2003–2015.

	ALL			AML
	0–14	15–24	25–39	0–14	15–24	25–39
Later (>3 days) initial treatment start
Unadjusted	0.39 (0.28–0.56)	1.00	1.53 (0.93–2.53)	0.17 (0.09–0.29)	1.00	1.22 (0.71–2.10)
Adjusted^b	0.39 (0.27–0.57)	1.00	1.47 (0.87–2.48)	0.16 (0.09–0.29)	1.00	0.88 (0.57–1.34)
Lacking treatment within 12 month following diagnosis
Unadjusted	0.18 (0.08–0.42)	1.00	0.71 (0.27–1.86)	0.54 (0.25–1.16)	1.00	1.33 (0.74–2.38)
Adjusted^b	0.17 (0.07–0.42)	1.00	0.58 (0.21–1.62)	0.53 (0.24–1.16)	1.00	1.14 (0.62–2.11)
Having chemotherapy + BMT/radiotherapy within 12 month following diagnosis
Unadjusted	0.23 (0.15–0.35)	1.00	2.03 (1.25–3.32)	0.69 (0.41–1.17)	1.00	0.93 (0.59–1.47)
Adjusted^b	0.22 (0.14–0.34)	1.00	2.21 (1.34–3.68)	0.69 (0.40–1.18)	1.00	0.99 (0.61–1.61)

^aOR: odds ratio from logistic regression analyses using 15–24-year group as reference. Outcomes were: later initial treatment start (initial treatment start >3 days vs ≤3 days), lacking treatment within 12 months following diagnosis (vs having treatment), and having chemotherapy and other treatment within 12 months following diagnosis (vs having chemotherapy only). ^badjusted for sex, country of birth, residential remoteness, SEIFA (socio-Economic Index for areas), and diagnosis period. Abbreviations: ALL: acute lymphoid leukemia; AML: acute myeloid leukemia.